LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Elenco Azioni・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Chiusa

28.71 0.35

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.72

Massimo

Metriche Chiave
By Trading Economics
Entrata	43M 13M
Vendite	29M 107M
EPS	0.25
Margine di Profitto	12.139
Dipendenti	524
EBITDA	16M 8.2M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+115.3% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	18M 1.5B
Apertura precedente	28.36
Chiusura precedente	28.71

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

27.895 / 30.16 Supporto e resistenza

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mag 2026, 22:27 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mag 2026, 22:12 UTC

Utili

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mag 2026, 21:52 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs

15 mag 2026, 00:00 UTC

Utili

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mag 2026, 23:57 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mag 2026, 23:56 UTC

Discorsi di Mercato

Gold Prices Rise on Strong Demand -- Market Talk

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mag 2026, 23:47 UTC

Utili

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mag 2026, 23:47 UTC

Utili

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mag 2026, 23:28 UTC

Discorsi di Mercato

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 mag 2026, 22:35 UTC

Discorsi di Mercato

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mag 2026, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mag 2026, 22:06 UTC

Discorsi di Mercato

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mag 2026, 22:04 UTC

Utili

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mag 2026, 22:00 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q EPS 18c >NU

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q Rev $4.97B >NU

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

115.3% in crescita

Previsioni per 12 mesi

Media 62.33 USD 115.3%

Alto 100 USD

Basso 33 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

27.895 / 30.16Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.